The National Institute on Drug Abuse has restructured its small business technology transfer and small business innovation research grant programs, which make up for roughly 2.8% of its annual budget, to focus on projects that aim to discover substance abuse treatments using translational and genetic medicine. "We're interested in areas of genetics, in terms of smoking cessation, pharmacogenomics, treatment of substance abuse, and particularly right now, issues related to prescription substance abuse," said NIDA official Jonathan D. Pollock. The NIH unit is also interested in supporting development and commercialization of biomarkers, stem cell reagents, genomic and proteomic data and related technologies.
NIDA shifts focus of grants to translational, genetic medicine
SmartBrief Job Listings for Health Care
|Manager of Provider Network Analytics||
Geisinger Health System
Yakima Valley Farm Workers Clinic
|Sr. Business Systems Analyst||
|Staff VP Medical Policy Development-81321||